PET imaging of a 68Ga labeled modified HER2 affibody in breast cancers: from xenografts to patients.
CONCLUSION: In summary, this study indicates the significant efficiency of the 68Ga labeled HER2 affibody. Preclinical and clinical studies support the possibility of monitoring HER2 levels in breast cancers using 68Ga-NOTA-MAL-Cys-MZHER2:342.
ADVANCES IN KNOWLEDGE: The research investigated the feasibility of a 68Ga labeled HER2 affibody modified with a hydrophilic linker for breast cancer PET imaging. Favorable outcomes showed that the probe might be valuable for determining HER2 status of the disease.
PMID: 31593482 [PubMed - as supplied by publisher]
Source: The British Journal of Radiology - Category: Radiology Authors: Xu Y, Wang L, Pan D, Yu C, Mi B, Huang Q, Sheng J, Yan J, Wang X, Yang R, Yang M Tags: Br J Radiol Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | PET Scan | Radiology | Study | UK Health | Urology & Nephrology